Recent Posts
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences
- Lifesaving Capital: How impact investing is shaping the future of biotech
- Investor Relations: the quiet advantage powering ASX microcaps
- HealthInvest Sydney: Life Sciences in the Investor Spotlight
- HealthInvest September 2025
Archives
A groundbreaking approach to cancer treatment
A number of breakthrough discoveries for Race Oncology's (ASX:RAC) drug Zantrene® over the past 18 months has seen the company evolve its strategy and clinical programs in order to maximise these opportunities. What does the future for Race look like?
